Patents by Inventor Roberto Maldonado

Roberto Maldonado has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220010337
    Abstract: Methods and compositions related to intracellular delivery of gene editing proteins are provided. The invention relates to compositions and methods for transporting gene editing polypeptides, such as Cas9 or Cas12, into a cell ex vivo or in vivo. The invention includes a targeted active gene editing (TAGE) agent that includes an extracellular cell membrane binding moiety, e.g., an antigen binding polypeptide, a cell penetrating peptide (CPP), a ligand, or combinations thereof, that specifically binds to an extracellular cell membrane-bound molecule (e.g., a cell surface molecule), and a site-directed modifying polypeptide that recognizes a nucleic acid sequence. The extracellular cell membrane binding moiety (e.g.
    Type: Application
    Filed: September 21, 2021
    Publication date: January 13, 2022
    Applicant: Spotlight Therapeutics
    Inventors: Hariharan Jayaram, Rina Mepani, Christopher Richardson, Steven Strutt, Eric Estrin, Jillian Astarita, Spencer Wei, Roberto Maldonado
  • Publication number: 20210307112
    Abstract: An apparatus, provided in use in a first device comprises at least one processor and at least one memory including a computer program code, the at least one memory and computer program code configured to, with the at least one processor, cause the apparatus at least to: receive first information about a context provided by a controller, said first information being received from a base station; and cause the first device to transmit one or more ping messages to one or more second devices, said one or more ping messages comprising information about said context which causes one or more second devices to reply to the controller.
    Type: Application
    Filed: March 30, 2021
    Publication date: September 30, 2021
    Inventors: Karsten Aarrebo Petersen, Bent Henneberg Rysgaard, István Zsolt Kovács, Troels Emil Kolding, Roberto Maldonado
  • Publication number: 20200360350
    Abstract: This invention relates to methods for reducing or preventing anaphylaxis to non-allergenic antigens with compositions comprising immunosuppressants, and related compositions.
    Type: Application
    Filed: April 24, 2020
    Publication date: November 19, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventor: Roberto A. Maldonado
  • Patent number: 10668053
    Abstract: This invention relates to methods for reducing or preventing anaphylaxis to non-allergenic antigens with compositions comprising immunosuppressants, and related compositions.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: June 2, 2020
    Assignee: Selecta Biosciences, Inc.
    Inventor: Roberto A. Maldonado
  • Publication number: 20200113874
    Abstract: Disclosed are compositions and methods that provide pharmacodynamic effects specific to therapeutic macromolecules. The effects may result from reduced doses of therapeutic macromolecules in combination with immunosuppressant doses. The effects may also be enhanced with such compositions.
    Type: Application
    Filed: August 26, 2019
    Publication date: April 16, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventors: Roberto A. Maldonado, Takashi Kei Kishimoto
  • Publication number: 20200101155
    Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells.
    Type: Application
    Filed: September 4, 2019
    Publication date: April 2, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventors: Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
  • Publication number: 20200101154
    Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering immunosuppressants and MHC Class I-restricted and/or MHC Class II-restricted epitopes that can generate tolerogenic immune responses (e.g., antigen-specific T effector cell deletion).
    Type: Application
    Filed: August 8, 2019
    Publication date: April 2, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
  • Publication number: 20200078341
    Abstract: Disclosed are methods and related compositions for concomitantly, locally administering immunosuppressants and doses of therapeutic macromolecules for reducing Type I and Type IV hypersensitivity.
    Type: Application
    Filed: June 11, 2019
    Publication date: March 12, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventor: Roberto A. Maldonado
  • Publication number: 20200069660
    Abstract: Disclosed are dosings of therapeutic macromolecules and immunosuppressants, in some embodiments attached to synthetic nanocarriers, in combination with dosings of therapeutic macromolecules without synthetic nanocarriers, and related methods that provide reduced humoral immune responses.
    Type: Application
    Filed: June 6, 2019
    Publication date: March 5, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventors: Roberto A. Maldonado, Takashi Kei Kishimoto
  • Patent number: 10441651
    Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: October 15, 2019
    Assignee: Selecta Biosciences, Inc.
    Inventors: Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
  • Patent number: 10434088
    Abstract: Disclosed are compositions and methods that provide pharmacodynamic effects specific to therapeutic macromolecules. The effects may result from reduced doses of therapeutic macromolecules in combination with immunosuppressant doses. The effects may also be enhanced with such compositions.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: October 8, 2019
    Assignee: Selecta Biosciences, Inc.
    Inventors: Roberto A. Maldonado, Takashi Kei Kishimoto
  • Patent number: 10420835
    Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering immunosuppressants and MHC Class I-restricted and/or MHC Class II-restricted epitopes that can generate tolerogenic immune responses (e.g., antigen-specific T effector cell deletion).
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: September 24, 2019
    Assignee: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
  • Patent number: 10357482
    Abstract: Disclosed are methods and related compositions for concomitantly, locally administering immunosuppressants and doses of therapeutic macromolecules for reducing Type I and Type IV hypersensitivity.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: July 23, 2019
    Assignee: Selecta Biosciences, Inc.
    Inventor: Roberto A. Maldonado
  • Patent number: 10357483
    Abstract: Disclosed are dosings of therapeutic macromolecules and immunosuppressants, in some embodiments attached to synthetic nanocarriers, in combination with dosings of therapeutic macromolecules without synthetic nanocarriers, and related methods that provide reduced humoral immune responses.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: July 23, 2019
    Assignee: Selecta Biosciences, Inc.
    Inventors: Roberto A. Maldonado, Takashi Kei Kishimoto
  • Publication number: 20190076522
    Abstract: Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods. The synthetic nanocarrier compositions may also include antigen in some embodiments.
    Type: Application
    Filed: August 6, 2018
    Publication date: March 14, 2019
    Applicant: Selecta Biosciences, Inc.
    Inventors: David H. Altreuter, Aaron P. Griset, Roberto A. Maldonado
  • Patent number: 10039822
    Abstract: Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods. The synthetic nanocarrier compositions may also include antigen in some embodiments.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: August 7, 2018
    Assignee: Selecta Biosciences, Inc.
    Inventors: David H. Altreuter, Aaron P. Griset, Roberto A. Maldonado
  • Patent number: 10004802
    Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: June 26, 2018
    Assignee: Selecta Biosciences, Inc.
    Inventors: Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
  • Patent number: 9993548
    Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising B cell and/or MHC Class II-restricted epitopes and immunosuppressants in order to generate tolerogenic immune responses, such as the generation of antigen-specific regulatory B cells.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: June 12, 2018
    Assignee: Selecta Biosciences, Inc.
    Inventor: Roberto A. Maldonado
  • Patent number: 9987354
    Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering immunosuppressants and MHC Class I-restricted and/or MHC Class II-restricted epitopes that can generate tolerogenic immune responses (e.g., antigen-specific T effector cell deletion).
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: June 5, 2018
    Assignee: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
  • Publication number: 20160279234
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.
    Type: Application
    Filed: March 4, 2016
    Publication date: September 29, 2016
    Applicant: SELECTA BIOSCIENCES, INC.
    Inventors: TAKASHI KEI KISHIMOTO, CHRISTOPHER FRASER, ROBERTO A. MALDONADO